Kuros Biosciences AG (KURN) - Total Assets

Latest as of June 2026: CHF120.15 Million CHF ≈ $151.90 Million USD

Based on the latest financial reports, Kuros Biosciences AG (KURN) holds total assets worth CHF120.15 Million CHF (≈ $151.90 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Kuros Biosciences AG - Total Assets Trend (2004–2025)

This chart illustrates how Kuros Biosciences AG's total assets have evolved over time, based on quarterly financial data. Also see KURN company net worth for the company's overall valuation and market capitalisation.

Kuros Biosciences AG - Asset Composition Analysis

Current Asset Composition (December 2025)

Kuros Biosciences AG's total assets of CHF120.15 Million consist of 61.1% current assets and 38.9% non-current assets. Review Kuros Biosciences AG (KURN) financial obligations to assess the company's total debt and financial obligations.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF0.00	14.6%
Accounts Receivable	CHF31.85 Million	29.7%
Inventory	CHF16.92 Million	15.8%
Property, Plant & Equipment	CHF4.68 Million	4.4%
Intangible Assets	CHF13.15 Million	12.3%
Goodwill	CHF19.25 Million	18.0%

Asset Composition Trend (2004–2025)

This chart illustrates how Kuros Biosciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Kuros Biosciences AG for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Kuros Biosciences AG's current assets represent 61.1% of total assets in 2025, a decrease from 76.1% in 2004.
Cash Position: Cash and equivalents constituted 14.6% of total assets in 2025, down from 23.8% in 2004.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2004.
Asset Diversification: The largest asset category is accounts receivable at 29.7% of total assets.

Kuros Biosciences AG Competitors by Total Assets

Key competitors of Kuros Biosciences AG based on total assets are shown below.

Company	Country	Total Assets
COCHLEAR LTD ADR 1/2/O.N. F:OC50	Germany	€2.83 Billion
TransMedics Group Inc NASDAQ:TMDX	USA	$1.46 Billion
Jiangsu Yuyue Medical Equipment & Supply Co Ltd SHE:002223	China	CN¥16.89 Billion
Novocure Ltd NASDAQ:NVCR	USA	$787.93 Million
Shenzhen New Industries Biomedical SHE:300832	China	CN¥9.58 Billion
Jafron Biomedical Co Ltd SHE:300529	China	CN¥5.20 Billion
Hangzhou AGS MedTech Co. Ltd. A SHG:688581	China	CN¥2.70 Billion
Nanjing Vishee Medical Technology Co Ltd SHG:688580	China	CN¥1.79 Billion

Kuros Biosciences AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.87	2.25	8.43
Quick Ratio	1.28	1.74	8.06
Cash Ratio	0.00	0.68	0.00
Working Capital	CHF31.25 Million	CHF33.76 Million	CHF27.77 Million

Kuros Biosciences AG - Advanced Valuation Insights

This section examines the relationship between Kuros Biosciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	10.34
Latest Market Cap to Assets Ratio	6.72
Asset Growth Rate (YoY)	26.8%
Total Assets	CHF107.21 Million
Market Capitalization	$720.86 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Kuros Biosciences AG's assets at a significant premium (6.72x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Kuros Biosciences AG's assets grew by 26.8% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Kuros Biosciences AG (2004–2025)

The table below shows the annual total assets of Kuros Biosciences AG from 2004 to 2025.

Year	Total Assets	Change
2025-12-31	CHF107.21 Million ≈ $135.55 Million	+26.82%
2024-12-31	CHF84.54 Million ≈ $106.88 Million	+18.29%
2023-12-31	CHF71.46 Million ≈ $90.35 Million	-13.84%
2022-12-31	CHF82.95 Million ≈ $104.87 Million	-9.19%
2021-12-31	CHF91.34 Million ≈ $115.47 Million	-3.21%
2020-12-31	CHF94.36 Million ≈ $119.30 Million	+7.41%
2019-12-31	CHF87.85 Million ≈ $111.07 Million	+2.37%
2018-12-31	CHF85.82 Million ≈ $108.50 Million	-0.30%
2017-12-31	CHF86.08 Million ≈ $108.83 Million	+96.68%
2016-12-31	CHF43.77 Million ≈ $55.33 Million	+1242.99%
2015-12-31	CHF3.26 Million ≈ $4.12 Million	-81.52%
2014-12-31	CHF17.63 Million ≈ $22.29 Million	-56.47%
2013-12-31	CHF40.50 Million ≈ $51.21 Million	+33.27%
2012-12-31	CHF30.39 Million ≈ $38.42 Million	-1.37%
2011-12-31	CHF30.81 Million ≈ $38.96 Million	-43.01%
2010-12-31	CHF54.07 Million ≈ $68.36 Million	-21.30%
2009-12-31	CHF68.70 Million ≈ $86.86 Million	-37.97%
2008-12-31	CHF110.75 Million ≈ $140.02 Million	-10.36%
2007-12-31	CHF123.56 Million ≈ $156.21 Million	+115.21%
2006-12-31	CHF57.41 Million ≈ $72.58 Million	-30.32%
2005-12-31	CHF82.39 Million ≈ $104.17 Million	-6.76%
2004-12-31	CHF88.37 Million ≈ $111.72 Million	--

About Kuros Biosciences AG

SW:KURN Switzerland Medical Devices

Market Cap

$846.66 Million

CHF669.68 Million CHF

Market Cap Rank

#10404 Global

#129 in Switzerland

Share Price

CHF16.88

Change (1 day)

-5.38%

52-Week Range

CHF16.88 - CHF33.36

All Time High

CHF36.96